The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
FREE Daily Email Newsletter
Government Stops Study Seeking To Prevent Type of Stroke
May 13, 2013 8:38 am | by LAURAN NEERGAARD,AP Medical Writer | News | CommentsThe government has halted a study testing treatments for a brain condition that can cause strokes after early results suggested invasive therapies were riskier than previously thought. The condition involves a kind of tangle in the brain called an arteriovenous malformation, or AVM. Arteries and veins grow knotted together until eventually some of them burst, causing a bleeding stroke.
FDA Accepts Biogen Idec’s BLA for Long-Lasting Factor VIII Therapy for Hemophilia A
May 13, 2013 8:31 am | News | CommentsBiogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.
Huge Drug Cost Disparities Seen in Health Overhaul
May 13, 2013 8:27 am | by RICARDO ALONSO-ZALDIVAR,Associated Press | News | CommentsCancer patients could face high costs for medications under President Barack Obama's health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you'll pay. To try to keep premiums low, some states are allowing insurers to charge patients a hefty share of the cost for expensive medications used to treat cancer, multiple sclerosis, rheumatoid arthritis and other life-altering chronic diseases.
Frazier Healthcare Acquires AndersonBrecon from AmerisourceBergen
May 13, 2013 8:17 am | News | CommentsFrazier Healthcare and Packaging Coordinators, Inc. today announced that they have completed the acquisition of pharmaceutical packager AndersonBrecon from its parent company AmerisourceBergen Corporation. AndersonBrecon will now merge with and operate as Packaging Coordinators, Inc.
Elan Enters $1B Royalty Deal with Theravance
May 13, 2013 8:12 am | by The Associated Press | News | CommentsIrish drugmaker Elan plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance and GlaxoSmithKline. The deal will give Elan 21 percent of the future royalties that Theravance Inc. receives from Glaxo. Theravance shares jumped 7 percent in premarket trading. Elan shares slipped.
FDA Denies Request to Block Generic Painkiller
May 10, 2013 5:53 pm | by The Associated Press | News | CommentsIn a surprise move Friday, federal health regulators denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued are more easily abused than its branded product. Endo's Opana ER is a long-acting narcotic drug used to treat moderate and...
Actavis, Warner Chilcott Discussing Combination
May 10, 2013 3:38 pm | by MARLEY SEAMAN - AP Business Writer - Associated Press | News | CommentsThe drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies. The companies say there is no guarantee that Actavis will make an offer for Warner Chilcott, however. Actavis expects to generate more than $8.1 billion...
Warner Chilcott 1Q Net Income Holds Steady
May 10, 2013 1:07 pm | by The Associated Press | News | CommentsIrish drugmaker Warner Chilcott PLC said Friday its net income held steady in the first quarter despite lower sales of some of its biggest products. The company said sales of its ulcerative colitis drug Asacol fell because it stopped selling one dose of the drug after receiving marketing approval...
Medical Experiment May Give Old Hearts a New Life
May 10, 2013 12:28 pm | by CBS | Videos | CommentsDoctors have seen promising results in an experiment that transfers a hormone from healthy mice to mice with heart failure. The hormone, GDF11, declines with age in mice, and the scientists took GDF11 from young, healthy mice giving it to old mice with heart failure. Dr. Jon LaPook reports the team's next step is to see if it has the same effect in humans.
Pain Therapeutics, Durect Fall on Remoxy Review
May 10, 2013 11:35 am | by The Associated Press | News | CommentsShares of Pain Therapeutics Inc. and Durect Corp. tumbled Friday after their partner Pfizer Inc. said it may not pursue further development of Remoxy, an experimental pain drug that has been plagued with delays in regulatory approval. Durect developed Remoxy and licensed it to Pain Therapeutics....
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
May 10, 2013 9:30 am | News | CommentsLexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial. LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).
Lilly's Enzastaurin Phase III Study Did Not Meet Primary Endpoint in DLBCL
May 10, 2013 9:15 am | News | CommentsEli Lilly and Company announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL).
Pfizer Executive Faces Porn Charges
May 9, 2013 6:23 pm | by The Associated Press | News | CommentsSAN JUAN, Puerto Rico (AP) — Federal authorities in Puerto Rico have arrested an executive at Pfizer Pharmaceutical for allegedly producing child pornography. Officials say 48-year-old Reinaldo Diaz Camacho was charged after Puerto Rico police received information that he was having sexually...
Collagenase/Neutral Protease Blends 1 and 2
May 9, 2013 3:42 pm | Product Releases | CommentsSTEMzyme™ 1 & 2 Collagenase/Neutral Protease (Dispase®) are specialized combinations of AOF Clostridium histolyticum Collagenase (Code: CLSAFB) and AOF Bacillus polymyxa Neutral Protease (Dispase®) with a minimum of 250 CLS units and 1,000 or 2,000 caseinase units per mg dry weight.
Benchtop Nutsche Filter Units
May 9, 2013 3:22 pm | Product Releases | CommentsPharmaceutical intermediates are efficiently filtered, washed, reslurried and dried in these portable nutsche filter units, minimizing contamination and exposure. Its design allows withdrawal of filter cake utilizing removable top head, bottom head and filter support assembly.
